5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.85▼ | 2.85▲ | 2.84▲ | 2.86▼ | 2.67▲ |
MA10 | 2.85▲ | 2.84▲ | 2.82▲ | 2.81▲ | 2.93▼ |
MA20 | 2.85▲ | 2.82▲ | 2.84▲ | 2.66▲ | 3.65▼ |
MA50 | 2.83▲ | 2.85▼ | 2.86▼ | 3.00▼ | 3.90▼ |
MA100 | 2.83▲ | 2.85▲ | 2.73▲ | 3.69▼ | 4.06▼ |
MA200 | 2.85▼ | 2.70▲ | 2.70▲ | 3.82▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.007▲ | 0.001▲ | 0.055▲ | -0.103▼ |
RSI | 52.876▲ | 52.746▲ | 51.550▲ | 51.072▲ | 38.383▼ |
STOCH | 80.556▲ | 78.062 | 65.375 | 80.830▲ | 20.771 |
WILL %R | -33.333 | -18.182▲ | -28.000 | -15.789▲ | -76.208▼ |
CCI | 29.885 | 66.164 | 53.256 | 59.041 | -51.920 |
Thursday, April 24, 2025 05:00 PM
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform ...
|
Wednesday, April 16, 2025 05:00 PM
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform ...
|
Monday, April 14, 2025 11:57 PM
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on MaxCyte (MXCT – Research Report). The company’s shares opened today at p194.40. Discover outperforming ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
02/05/25 | 2.87 | 2.87 | 2.83 | 2.85 | 86,688 |
01/05/25 | 2.85 | 2.875 | 2.755 | 2.79 | 315,952 |
30/04/25 | 2.86 | 2.885 | 2.80 | 2.84 | 562,319 |
29/04/25 | 2.93 | 2.93 | 2.87 | 2.90 | 426,158 |
28/04/25 | 2.88 | 2.955 | 2.83 | 2.92 | 868,533 |
25/04/25 | 2.85 | 2.88 | 2.79 | 2.88 | 289,873 |
24/04/25 | 2.82 | 2.89 | 2.78 | 2.84 | 429,366 |
23/04/25 | 2.78 | 2.89 | 2.71 | 2.81 | 1,412,827 |
22/04/25 | 2.61 | 2.84 | 2.61 | 2.73 | 629,031 |
21/04/25 | 2.57 | 2.675 | 2.53 | 2.57 | 545,524 |
|
|
||||
|
|
||||
|
|